Digestive Diseases and Sciences

, Volume 56, Issue 7, pp 2137–2144

Clinical Significance of Perihepatic Lymphadenopathy in Patients with Chronic Hepatitis C Infection

Original Article

Abstract

Background

Patients with chronic hepatitis C (HCV) infection commonly have perihepatic lymph node enlargement (PLNE). We investigated the prognostic value of PLNE in the development of complicated cirrhosis and death, as well as the clinical and laboratory factors associated with the presence of PLNE in a cohort of HCV-infected veterans.

Methods

Using a retrospective cohort design, we compared the rate of development of decompensated cirrhosis and/or death in a group of HCV-infected patients who did not have evidence of decompensated cirrhosis stratified by the presence or absence of PLNE. We used Kaplan–Meier survival curves. We then evaluated which factors were predictive of detection of PLNE using logistic regression.

Results

A total of 131 patients were included in the study. Fifty-nine patients had PLNE and 72 patients did not. After a mean follow-up of 42 months, survival in the absence of progression to decompensated cirrhosis and/or death was not significantly different between the two groups (log-rank test, p = 0.27). The only factor predictive of progression to decompensated cirrhosis and/or death was the presence of cirrhosis at baseline (HR 13.13, 95% CI 2.21–79.41). In addition, cirrhosis was the only factor predictive of the detection of PLNE on CT scan (OR 3.09: CI 2.1–25.9).

Conclusions

Presence of PLNE in patients with chronic HCV infection is strongly associated with subclinical cirrhosis. However, PLNE does not independently predict the progression of liver disease to decompensated cirrhosis and/or death in HCV-infected patients.

Keywords

Hepatitis C Cirrhosis Perihepatic lymphadenopathy Prognosis 

References

  1. 1.
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhhert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States. Ann Intern Med. 2006;144:705–714.PubMedGoogle Scholar
  2. 2.
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–S50.PubMedCrossRefGoogle Scholar
  3. 3.
    Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383–398.PubMedCrossRefGoogle Scholar
  4. 4.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.PubMedCrossRefGoogle Scholar
  5. 5.
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421–430.PubMedCrossRefGoogle Scholar
  6. 6.
    Moore KL, Dalley AF, Agur AMR. Clinically oriented anatomy. 5th ed. Philadelphia, PA: Lippincott, Williams, & Wilkins; 2006:298–299.Google Scholar
  7. 7.
    Cassani F, Valentini P, Cataleta M, et al. Ultrasound-detected abdominal lymphadenopathy in chronic hepatitis C: high frequency and relationship with viremia. J Hepatol. 1997;26:479–483.PubMedCrossRefGoogle Scholar
  8. 8.
    Spinetti A, Matricardi L, Puoti M, et al. Ultrasound evaluation of hepatic lymph nodes in patients with anti-hepatitis C virus antibody reactivity. Ital J Gastroenterol Hepatol. 1999;31:295–330.PubMedGoogle Scholar
  9. 9.
    Maeda T, Hori Y, Yamaguchi N, et al. Clinical significance of lymphadenopathy in the upper abdomen: ultrasound demonstration. Nippon Acta Radiogica. 1995;55:228–232.Google Scholar
  10. 10.
    Choi MS, Lee JH, Koh KC, et al. Clinical significance of enlarged perihepatic lymph nodes in chronic hepatitis B. J Clin Gastroenterol. 2001;32:329–332.PubMedCrossRefGoogle Scholar
  11. 11.
    Dietrich CF, Zeuzem S, Caspary WF, Wehrmann T. Ultrasound lymph node imaging in the abdomen and retroperitoneum of healthy probands. Ultraschall Med. 1998;19:265–269.PubMedCrossRefGoogle Scholar
  12. 12.
    Kuo H, Lin C, Chen J, Tsai S. Enlarged lymph nodes in porta hepatis: sonographic sign of chronic hepatitis B and C infections. J Clin Ultrasound. 2006;34:211–216.PubMedCrossRefGoogle Scholar
  13. 13.
    Watanabe T, Sassa T, Hiratsuka H, Hattori S, Abe A. Clinical significance of enlarged perihepatic lymph node on ultrasonography. Eur J Gastroenterol Hepatol. 2005;17:185–190.PubMedCrossRefGoogle Scholar
  14. 14.
    Dietrich CF, Lee J, Herrmann G, et al. Enlargement of perihepatic lymph nodes in relation to liver histology and viremia in patients with chronic hepatitis C. Hepatology. 1997;26:467–472.PubMedCrossRefGoogle Scholar
  15. 15.
    Soresi M, Bonfissuto G, Magliarisi C, et al. Ultrasound detection of abdominal lymph nodes in chronic liver diseases: a retrospective analysis. Clin Radiol. 2003;58:372–377.PubMedCrossRefGoogle Scholar
  16. 16.
    Dietrich CF, Stryjek-Kaminska D, Teuber G, Lee J, Caspary WF, Zeuzem S. Perihepatic lymph nodes as a marker of antiviral response in patients with chronic hepatitis C infection. Am J Roentgenol. 2000;174:699–704.Google Scholar
  17. 17.
    Soresi M, Bonfissuto G, Sesti R, et al. Perihepatic lymph nodes and antiviral response in chronic HCV-associated hepatitis. Ultrasound Med Biol. 2004;30:711–717.PubMedCrossRefGoogle Scholar
  18. 18.
    Dofman RE, Alpern MB, Gross BH, Sandler MA. Upper abdominal lymph node: criteria for normal size determined with CT. Radiology. 1991;180:319–322.Google Scholar
  19. 19.
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhner WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.PubMedGoogle Scholar
  20. 20.
    Richardson D, Fisher M, Sabin CA. Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. J Infect Dis. 2008;197:1213–1214.PubMedCrossRefGoogle Scholar
  21. 21.
    Van de Laar TJW, Van Der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis. 2007;196:230–238.PubMedCrossRefGoogle Scholar
  22. 22.
    Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008; 135:451–458. 2008 May 27.Google Scholar
  23. 23.
    Kudo M, Zheng RQ, Kim SR, et al. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis: a multicenter collaborative study. Intervirology. 2008;51:17–25.PubMedCrossRefGoogle Scholar
  24. 24.
    Di Bisceglie AM, Sterling RK, Chung RT. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial. J Hepatol. 2005;43:434–441.PubMedCrossRefGoogle Scholar
  25. 25.
    Wai C, Greenson JK, Fontana RJ, Kalbfleisch JD. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.PubMedCrossRefGoogle Scholar
  26. 26.
    Bayati N, Silverman AL, Stuart GC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gasteroenterol. 1998;93:2452–2456.CrossRefGoogle Scholar
  27. 27.
    Choi, PC, Kim HJ, Choi WH, Park D, Park JH, Cho YK, et al. Model for end-stage liver disease, model for end-stage liver disease-sodium and Child-Turcotte-Pugh scores over time for the prediction of complications of liver cirrhosis. Liver international 2009; 221–226.Google Scholar
  28. 28.
    Soresi M, Carroccio A, Agate V, et al. Evaluation by ultrasound of abdominal lymphadenopathy in chronic hepatitis C. Am J Gastroenterol. 1999;94:497–501.PubMedCrossRefGoogle Scholar
  29. 29.
    Dod GD, Baron RL, Oliver JH, Federle MP, Baumgartel PB. Enlarged abdominal lymph nodes in end-stage cirrhosis: CT-histopathologic correlation in 507 patients. Radiology. 1997;203:127–130.Google Scholar
  30. 30.
    Saadoun D, Asselah T, Resche-Rigon M, Charlotte F, Bedossa P, Valla D, Piette JC, Marcellin P, Cacoub P. Hepatology 2006; 43:1337–1345.Google Scholar
  31. 31.
    Muller P, Renou C, Harafa A, et al. Lymph node enlargement within the hepatoduodenal ligament in patients with chronic hepatitis C reflects the immunological cellular response of the host. J Hepatol. 2003;39:807–813.PubMedCrossRefGoogle Scholar
  32. 32.
    Adinolfi LE, Utili R, Andreana A, et al. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci. 2001;46:1677–1683.PubMedCrossRefGoogle Scholar
  33. 33.
    Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gasteroenterol. 2007;42:513–521.CrossRefGoogle Scholar
  34. 34.
    Roselle GA, Danko LH, Kralovic SM, Simbartl LA, Kizer KW. National hepatitis C surveillance day in the veterans health administration of the department of veterans affairs. Mil Med. 2002;167:756–759.PubMedGoogle Scholar
  35. 35.
    Briggs ME, Baker C, Hall R, et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology. 2001;34:1200–1205.PubMedCrossRefGoogle Scholar
  36. 36.
    Ishii H, Saito H. Perihepatic lymphadenopathy in chronic liver disease. J Gasteroenterol Hepatol. 2000;15:695–696.CrossRefGoogle Scholar
  37. 37.
    Neri S, Ierna D, Mauceri B, et al. Can ultrasounographic findings of perihepatic lymphadenopathy promote investigation to detect possible presence of virus C infection in non-symptomatic subjects? Hepatol Res. 2003;27:124–128.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Michael E DeBakey Veterans Affairs Medical CenterHoustonUSA
  2. 2.Baylor College of MedicineHoustonUSA

Personalised recommendations